7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-A]pyrimidin-5-ones for the treatment of thrombotic disorders

US9303044B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• The Rockefeller University · US
• ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · US

Inventors

• Barry S. Coller · New York, US
• Craig J. Thomas · Gaithersburg, US
• Marta Filizola · Yonkers, US
• Joshua McCoy · Portland, US
• Wenwei Huang · Rockville, US
• Min-Jui Richard Shen · Boyds, US
• Jian-Kang Jiang · Columbia, US

Key dates

• Filing date: Jan 16, 2013
• Grant date: Apr 5, 2016
• Expiry date: Jan 16, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61L2300/45
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds and compositions of Formula P useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The definitions of variables A, B, R2, R3, R4, Ra, Ra′, Rb, Rb′, Rc, Rd, Rd′, Re, and Re′ are provided in the disclosure. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.